Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib in Relapsed/Refractory B-ALL
NCT02129062Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Apr 2014
- Primary completion
- Nov 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ibrutinib in B cell acute lymphoblastic leukemia (B-ALL), sponsored by National Cancer Institute. Started Apr 2014; status: terminated.
02
Drugs
ibrutinib
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT02129062.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02129062.